performance status

Open Access
The Role of Salvage Chemotherapy on Survival Outcomes Following Immune Checkpoint Inhibitor Therapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
DAISUKE ABE, TAKAYUKI KIMURA, SATORU KOIKE, HISATOMO TAMAKI, SAYUMI KONYA, MAYA KAWAMOTO, MASAHIRO UMEMOTO, MITSUO SATO, MUTSUKAZU KITANO, TAKAHIRO WAKASAKI and RYUJI YASUMATSU

In Vivo September 2025, 39 (5) 2993-3000; DOI: https://doi.org/10.21873/invivo.14100
Open Access
Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing
NOBUKI FURUBAYASHI, MANABU MOCHIDA, ATSUHIRO KIJIMA, YUSHI FUJIMOTO, MOTONOBU NAKAMURA and TAKAHITO NEGISHI

In Vivo March 2025, 39 (2) 976-987; DOI: https://doi.org/10.21873/invivo.13903
Open Access
Effectiveness of Chemoimmunotherapy in Small-cell Lung Cancer Patients With a Poor Performance Status or Higher Neutrophil/Lymphocyte Ratio
MINEHIKO INOMATA, NAOKI TAKATA, ZENTA SETO, NOZOMU MURAYAMA, KOTARO TOKUI, SEISUKE OKAZAWA, SHINGO IMANISHI, TOSHIRO MIWA, RYUJI HAYASHI and SHOKO MATSUI

In Vivo January 2025, 39 (1) 467-472; DOI: https://doi.org/10.21873/invivo.13850
You have access
Symptom Burden in Patients With Reduced Performance Status at the Start of Palliative Radiotherapy
CARSTEN NIEDER and THOMAS A. KÄMPE

In Vivo March 2020, 34 (2) 735-738; DOI: https://doi.org/10.21873/invivo.11832
You have access
A Survival Score Based on Symptoms and Performance Status for Patients with High-grade Gliomas Receiving Radiochemotherapy
PHAM CAM PHUONG, LE VIET NAM, STEVEN E. SCHILD, DIRK RADES and MAI TRONG KHOA

In Vivo July 2017, 31 (4) 689-693;

Main menu

User menu

Search

performance status